Lyell Immunopharma, Inc.
LYEL
$22.31
$1.507.21%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 41.00K | 60.00K | 65.00K | 61.00K | 63.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.00K | 60.00K | 65.00K | 61.00K | 63.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 41.00K | 60.00K | 65.00K | 61.00K | 63.00K |
| SG&A Expenses | 49.04M | 50.12M | 52.59M | 52.04M | 50.69M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -5.78M | -4.92M | -4.55M | -4.25M | -3.89M |
| Total Operating Expenses | 198.41M | 211.68M | 219.92M | 219.40M | 216.73M |
| Operating Income | -198.37M | -211.62M | -219.85M | -219.34M | -216.66M |
| Income Before Tax | -325.66M | -331.40M | -334.52M | -342.99M | -203.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -325.66 | -331.40 | -334.52 | -342.99 | -203.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -325.66M | -331.40M | -334.52M | -342.99M | -203.99M |
| EBIT | -198.37M | -211.62M | -219.85M | -219.34M | -216.66M |
| EBITDA | -184.20M | -195.34M | -201.80M | -199.70M | -197.00M |
| EPS Basic | -22.26 | -23.61 | -24.32 | -25.55 | -16.03 |
| Normalized Basic EPS | -7.64 | -8.48 | -9.08 | -9.35 | -9.43 |
| EPS Diluted | -22.26 | -23.61 | -24.32 | -25.55 | -16.03 |
| Normalized Diluted EPS | -7.64 | -8.48 | -9.08 | -9.35 | -9.43 |
| Average Basic Shares Outstanding | 61.81M | 56.36M | 54.34M | 52.30M | 50.94M |
| Average Diluted Shares Outstanding | 61.81M | 56.36M | 54.34M | 52.30M | 50.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |